PF-03446962 in Relapsed or Refractory Urothelial Cancer

NCT01620970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Transitional Cell Carcinoma of Bladder

Interventions

DRUG: PF03446962

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano